Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $78

Benzinga Newsdesk www.benzinga.com Neutral 61.3%

Neg 0% Neu 61.3% Pos 0%

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and lowers the price target from $80 to $78.